The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit ...

Gene Munster, Deepwater Asset Management managing partner, joins 'Squawk Box' to discuss the uncertainty facing Apple, President Trump's 25% iPhone tariff threat, the pressure facing CEO Tim Cook, the ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that the Company will participate in the ...

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future of vaccine development in the U.S. faces growing challenges, including ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...